About Us
Corporate Overview
Executive Leadership
Management team
Scientific Advisory Board
Board of Directors
Our Science
Pipeline
Overview
AG-73305
AG-80308
AG-86893
Disease
Overview
DME
nAMD
Other Diseases
Pterygium
Dry Eye
Clinical Trial
Investor Relations
Investors
Press Release & Publications
Contact Us
News
2023-09-30
Allgenesis to Present Initial Data from Phase 2a Study of AG-73305, a Novel Bispecific Anti-VEGF and Anti-Integrin Fc-Fusion Protein for the Treatment of DME at AAO 2023
Read more
2023-06-19
Allgenesis Announces Encouraging Phase 1b Data Showing AG-80308 Providing Improvements in Multiple Signs and Symptoms in Dry Eye Patients
Read more
2023-05-29
Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema
Read more
2023-04-18
Allgenesis Announces Last Patient Enrolled in the Phase 2a Trial Evaluating the Safety and Efficacy of AG-73305 in Diabetic Macular Edema (DME) Patients
Read more
2022-06-20
Allgenesis Announces First Patient Dosed in the U.S. for the Phase 1b trial Evaluating AG-80308 for the Treatment of Dry Eye Disease
Read more
